TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21375021

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with dietary adjustments and aerobic exercise
Number of subjects: 61

Group type: COMPARATOR
Intervention: Dietary adjustments and aerobic exercise
Number of subjects: 61
Study: 18054551

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (1 night with ≤3 hours of sleep)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sufficient sleep (3 days with ≥7 hours sleep/night)
Number of subjects: 20
Study: 15631892

Group type: EXPERIMENTAL
Intervention: C1 complement component
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C3 complement component
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C4 complement component
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C2 complement component
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total hemolytic activity of complement
Number of subjects: 0
Study: 12128243

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 118
Study: 10092996

Group type: EXPERIMENTAL
Intervention: Antioxidants or omega‐3 fatty acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary intake of vegetables, vitamin C, beta‐carotene, folate, vitamin B12, omega‐3 fatty acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cysteinylglycine and vitamin B12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Folate in serum and blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homocysteine
Number of subjects: 0
Study: 7753957

Group type: COMPARATOR
Intervention: 0.0 mg nicotine polacrilex
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0.5 mg nicotine polacrilex
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1.0 mg nicotine polacrilex
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2.0 mg nicotine polacrilex
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 4.0 mg nicotine polacrilex
Number of subjects: 21
Study: 2138590

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol maleate 0.5% vs Placebo
Number of subjects: 0
Study: 31568675

Group type: EXPERIMENTAL
Intervention: Testosterone (Sustanon 250 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 18
Study: 29295808

Group type: EXPERIMENTAL
Intervention: eHealth intervention (website and mobile app with personalized convalescence plan, information about surgery and recovery, eConsult, activity tracker)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: eConsult function
Number of subjects: 344
Study: 27966406

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention preceding infertility treatment
Number of subjects: 577

Group type: COMPARATOR
Intervention: Prompt infertility treatment
Number of subjects: 577
Study: 25189222

Group type: EXPERIMENTAL
Intervention: PCT-guided antimicrobial therapy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Standard antimicrobial therapy (control group)
Number of subjects: 169
Study: 22277317

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES; Endeavor Sprint®)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES; Cypher®)
Number of subjects: 160
Study: 20186574

Group type: EXPERIMENTAL
Intervention: Tailored print communication (TPC) + Telephone motivational interviewing (TMI)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 266
Study: 17978254

Group type: EXPERIMENTAL
Intervention: Executive Interview (EXIT) scores for employed group
Number of subjects: 213

Group type: COMPARATOR
Intervention: Executive Interview (EXIT) scores for unemployed group
Number of subjects: 213

Group type: COMPARATOR
Intervention: Lifetime psychiatric hospitalizations
Number of subjects: 213

Group type: COMPARATOR
Intervention: Number of psychotropic medications prescribed
Number of subjects: 213

Group type: COMPARATOR
Intervention: Executive functioning
Number of subjects: 213
Study: 15805340

Group type: EXPERIMENTAL
Intervention: 0.5 mg lidocaine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 0.25 mg lidocaine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 11940288

Group type: EXPERIMENTAL
Intervention: Thrombolysis combined with anticoagulant therapy
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy alone
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Pure anticoagulant therapy
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (combined)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 127
Study: 9871816

Group type: EXPERIMENTAL
Intervention: Citalopram (20 or 40 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 or 100 mg/day)
Number of subjects: 0
Study: 7620114

Group type: EXPERIMENTAL
Intervention: Loxoprofen sodium 60 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Indomethacin 25 mg
Number of subjects: 5
Study: 2231215

Group type: EXPERIMENTAL
Intervention: Ribavirin (n = 20)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Water placebo aerosol (n = 27)
Number of subjects: 178
Study: 339995

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rifampicin and dapsone for six months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dapsone alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rifampicin alone
Number of subjects: 100
Study: 31972765

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Extended-release naltrexone
Number of subjects: 60
Study: 31196505

Group type: EXPERIMENTAL
Intervention: Delayed-motion protocol
Number of subjects: 58

Group type: COMPARATOR
Intervention: Early-motion protocol
Number of subjects: 58

Group type: COMPARATOR
Intervention: Noncompliant patients with shoulder immobilizer
Number of subjects: 58

Group type: COMPARATOR
Intervention: Patients with torn rotator cuffs at 6 months
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Patients with greater improvements in QOL
Number of subjects: 58
Study: 27530992

Group type: EXPERIMENTAL
Intervention: Simulation with standardized patients (SPs)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires
Number of subjects: 26
Study: 25851052

Group type: EXPERIMENTAL
Intervention: TDF 300 mg daily from 30-32 weeks of gestation until 1 month postpartum
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: TDF 300 mg daily
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 118
Study: 23303244

Group type: EXPERIMENTAL
Intervention: Ringers acetate (20 ml/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 (10 ml/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of Ringers acetate and hydroxyethyl starch
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall bias across all pairs of measurements
Number of subjects: 10
Study: 20400652

Group type: EXPERIMENTAL
Intervention: Metoprolol immediate-release (IR) 50 mg with paroxetine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoprolol extended-release (ER) 100 mg with paroxetine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metoprolol immediate-release (IR) without paroxetine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metoprolol extended-release (ER) without paroxetine
Number of subjects: 10
Study: 17997395

Group type: EXPERIMENTAL
Intervention: Functional Adaptation and Skills Training (FAST)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Attention-Control (AC)
Number of subjects: 240
Study: 15984972

Group type: EXPERIMENTAL
Intervention: Hemoclips
Number of subjects: 47

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 47
Study: 12124862

Group type: EXPERIMENTAL
Intervention: Avoidance of activity
Number of subjects: 107
Study: 10608721

Group type: EXPERIMENTAL
Intervention: Protein A immunoadsorption (Immunosorba, Excorim AB, Lund, Sweden)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Thymectomy
Number of subjects: 4
Study: 7576170

Group type: EXPERIMENTAL
Intervention: Normal saline infusion (n = 35)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (n = 38)
Number of subjects: 73
Study: 1954070

Group type: EXPERIMENTAL
Intervention: Apomorphine (1 microgram kg‐1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Apomorphine (5 micrograms kg‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 6168823

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 24
Study: 29660807

Group type: EXPERIMENTAL
Intervention: KingVision 'sniffing'
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: KingVision neutral
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: C-MAC 'sniffing'
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: C-MAC neutral
Number of subjects: 200

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 200
Study: 28508838

Group type: EXPERIMENTAL
Intervention: Intra-hepatic arterial weekly high-dose 5-fluorouracil (WHF)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Continuous venous infusion of 5-fluorouracil (CVI)
Number of subjects: 91
Study: 26147923

Group type: EXPERIMENTAL
Intervention: Menstrual Cup (MC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cervicovaginal Lavage (CVL)
Number of subjects: 40
Study: 22804816

Group type: EXPERIMENTAL
Intervention: Titanium mucosal surfaces
Number of subjects: 19

Group type: COMPARATOR
Intervention: Reinforced composite resin mucosal surfaces
Number of subjects: 19

Group type: COMPARATOR
Intervention: Acrylic resin mucosal surfaces
Number of subjects: 19
Study: 21370262

Group type: EXPERIMENTAL
Intervention: 0.25 mg pramipexole
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5 mg ropinirole
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 18639987

Group type: EXPERIMENTAL
Intervention: Moderate physical activity (median=1.65 kcal/kg/day expended from physical activity)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 620
Study: 16631247

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg x 3) with mental stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg x 3) with exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg x 3) after postexercise meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated caffeine doses throughout the test day
Number of subjects: 0
Study: 15476475

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 71
Study: 11174054

Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 16
Study: 9022870

Group type: EXPERIMENTAL
Intervention: Current dieting for weight loss or weight maintenance
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Current dieters and those with an extensive history of dieting
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Weight suppression
Number of subjects: 999
Study: 8385975

Group type: EXPERIMENTAL
Intervention: i.v. magnesium sulphate 1 g h‐1 over 8 h
Number of subjects: 16

Group type: COMPARATOR
Intervention: NaCl 18 mg h‐1 (control)
Number of subjects: 16
Study: 3825543

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily for 30 days (extended to 3 months for 3 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Antacids 350 mmol daily for 30 days (extended to 3 months for 4 patients)
Number of subjects: 20
Study: 28796989

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (NaP) solution
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: NaP enema
Number of subjects: 293

Group type: COMPARATOR
Intervention: Fasting only
Number of subjects: 293
Study: 27476581

Group type: EXPERIMENTAL
Intervention: Camicinal (50 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 24530920

Group type: EXPERIMENTAL
Intervention: Glass fibre posts
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cast metal posts
Number of subjects: 54
Study: 22750353

Group type: EXPERIMENTAL
Intervention: Non‐Communicating Adults Pain Checklist (NCAPC)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Randomized group of participants (N=89)
Number of subjects: 228
Study: 20067974

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg b.i.d.
Number of subjects: 258

Group type: COMPARATOR
Intervention: Glimepiride up to 6 mg q.d.
Number of subjects: 258
Study: 18703934

Group type: COMPARATOR
Intervention: Lithium (starting dose: 400 mg/day)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Valproate (starting dose: 20 mg/kg/day)
Number of subjects: 300
Study: 16319295

Group type: EXPERIMENTAL
Intervention: Genetic strategies including linkage and association studies, pharmacogenetics, and gene x environment interactions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroendocrine supplementation (thyroid and testosterone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytokine pathways
Number of subjects: 0
Study: 15307437

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment (40 mg/kg) - first treatment
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment (40 mg/kg) - second treatment
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment (40 mg/kg) - side effects
Number of subjects: 482
Study: 8621174

Group type: EXPERIMENTAL
Intervention: Corticosteroid priming
Number of subjects: 38

Group type: COMPARATOR
Intervention: Interferon only
Number of subjects: 38
Study: 8466067

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine and opioids
Number of subjects: 153

Group type: COMPARATOR
Intervention: Parenteral opioids
Number of subjects: 153
Study: 2862814

Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Orciprenaline 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prenalterol 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terbutaline 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29873684

Group type: EXPERIMENTAL
Intervention: Oxaliplatin added to 5-FU-based chemoradiotherapy and adjuvant chemotherapy in patients aged <60 years
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Oxaliplatin added to 5-FU-based chemoradiotherapy and adjuvant chemotherapy in patients aged 40-70 years
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Control group (patients aged ≥70 years)
Number of subjects: 1232
Study: 26832656

Group type: EXPERIMENTAL
Intervention: High-Resolution Manometry (HRM)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Conventional Manometry (CM)
Number of subjects: 245
Study: 24187121

Group type: EXPERIMENTAL
Intervention: Building Healthy Children (BHC) intervention including Parents as Teachers, child-parent psychotherapy, and interpersonal psychotherapy as needed.
Number of subjects: 497

Group type: COMPARATOR
Intervention: Screening and referral to community services only (control group).
Number of subjects: 497
Study: 21435238

Group type: EXPERIMENTAL
Intervention: Birth on a birth seat
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Any other position (control group)
Number of subjects: 1002
Study: 19393850

Group type: EXPERIMENTAL
Intervention: Test product (Integrol(R)) 10 mg tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference product (Zyprexa(R)) 10 mg tablet
Number of subjects: 24
Study: 17596577

Group type: EXPERIMENTAL
Intervention: Biomarker-adaptive design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional trial design
Number of subjects: 0
Study: 15325831

Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg once daily
Number of subjects: 18325

Group type: COMPARATOR
Intervention: non-steroidal anti-inflammatory drugs (naproxen 500 mg twice daily or ibuprofen 800 mg three times daily)
Number of subjects: 18325

Group type: COMPARATOR
Intervention: non-steroidal anti-inflammatory drugs
Number of subjects: 18325
Study: 11215327

Group type: EXPERIMENTAL
Intervention: Controlled release dihydrocodeine (DHC) 60 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Controlled release dihydrocodeine (DHC) 120 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9605982

Group type: EXPERIMENTAL
Intervention: HIV-1 immunogen (Remune)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 0
Study: 7871098

Group type: COMPARATOR
Intervention: 0.5 g/kg ethanol
Number of subjects: 27

Group type: COMPARATOR
Intervention: 20 mg diazepam
Number of subjects: 27
Study: 2899329

Group type: EXPERIMENTAL
Intervention: oxazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: chlorprothixene
Number of subjects: 40
Study: 31678559

Group type: EXPERIMENTAL
Intervention: LASIK Xtra (30 mW/cm2, 90 seconds with continuous ultraviolet‐A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: convLASIK
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: LASIK Xtra
Number of subjects: 26
Study: 30592963

Group type: EXPERIMENTAL
Intervention: FOLFOX-6 regimen with L-carnosine (500 mg daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: FOLFOX-6 regimen without L-carnosine
Number of subjects: 65
Study: 28477428

Group type: EXPERIMENTAL
Intervention: ivacaftor 150 mg alone (study A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ivacaftor 150 mg plus ritonavir 50 mg daily (study B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ivacaftor 150 mg plus ritonavir 50 mg daily after two weeks of ritonavir 50 mg daily (study C)
Number of subjects: 12
Study: 24779558

Group type: EXPERIMENTAL
Intervention: Professional Identity Development Program (10 sessions, implemented once a week)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study: 23680943

Group type: EXPERIMENTAL
Intervention: 20 mg citalopram
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 20868630

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Baseline BOLD responses in left fusiform gyrus
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Baseline BOLD responses in right rolandic operculum
Number of subjects: 24
Study: 18435837

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC) for 15 minutes prior to and throughout heel lance procedure
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control condition (prone position swaddled in a blanket in the incubator)
Number of subjects: 61
Study: 21667097

Group type: COMPARATOR
Intervention: Paroxysmal AF (n = 63)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Persistent AF (n = 34)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Long-term persistent AF (n = 18)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Overall follow-up after ablative treatment
Number of subjects: 115
Study: 16131698

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500 or 1000 mg/d for 2 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 12
Study: 11881902

Group type: EXPERIMENTAL
Intervention: Knowledge of Results (KR) in a reproduction task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowledge of Results (KR) in a production task
Number of subjects: 0
Study: 9553213

Group type: EXPERIMENTAL
Intervention: Regional application of opioids via pump systems
Number of subjects: 0
Study: 7666815

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - either peroral or transdermal 17‐beta‐oestradiol with cyclic addition of dydrogesterone or 2.5 mg Tibolone (Org OD 14) in a daily peroral dose
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 105
Study: 2635446

Group type: EXPERIMENTAL
Intervention: Pentoxiphyllin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 326302

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg) and Acetazolamide (500 mg) in combination
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle (inert tablets)
Number of subjects: 8
Study: 30592724

Group type: EXPERIMENTAL
Intervention: Oxymizer
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional Nasal Cannula (CNC)
Number of subjects: 24
Study: 27866187

Group type: COMPARATOR
Intervention: Whey protein supplementation (24 g PRO)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Whey protein plus creatine supplementation (24 g PRO + 5 g creatine)
Number of subjects: 17
Study: 25001543

Group type: EXPERIMENTAL
Intervention: Social-communicatively cued goal-directed intention understanding in children with ASD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Object-oriented intention understanding in children with ASD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention to the experimenter's face during trials
Number of subjects: 0
Study: 22944053

Group type: EXPERIMENTAL
Intervention: tianmaixiaoke tablet 240 mg bid for 24 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: sitagliptin 100 mg qd for 24 weeks
Number of subjects: 84
Study: 21115586

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine
Number of subjects: 1804

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1804
Study: 17702654

Group type: EXPERIMENTAL
Intervention: Full‐length Lycra stinger suit (S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal swimwear (SW)
Number of subjects: 0
Study: 16417772

Group type: EXPERIMENTAL
Intervention: Qingqiao Capsule (QQC), 5 capsules each time, 3 times a day for 10-14 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cefaclor capsules, 0.5 g each time for adults, 3 times a day, or 20 mg/(kg.d) for children, for 10-14 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Qingqiao Capsule (QQC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cefaclor capsules
Number of subjects: 90